article thumbnail

Long-term COVID-19 containment will be shaped by strength, duration of immunity

Scienmag

Credit: Tumisu from Pixabay New research suggests that the impact of natural and vaccine-induced immunity will be key factors in shaping the future trajectory of the global coronavirus pandemic, known as COVID-19.

article thumbnail

New research will allow convenient investigation of human innate immune response to viral infections

Scienmag

(Boston)–Researchers from Boston University School of Medicine (BUSM) report the formation of human cells containing a green fluorescent protein or GFP (one of the most important proteins in biology and fluorescence imaging) genetically fused with two interferon stimulated genes (ISGs), namely Viperin and ISG15.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Experimental COVID-19 vaccine offers long-term protection against severe disease

Medical Xpress

In 2021, a group of scientists led by researchers at the University of North Carolina at Chapel Hill, Weill Cornell Medicine and NewYork-Presbyterian reported that the Moderna mRNA vaccine and a protein-based vaccine candidate containing an adjuvant, a substance that enhances immune responses, elicited durable neutralizing antibody responses to SARS-CoV-2 (..)

article thumbnail

Vitamin E from palm oil useful in boosting immune response based on studies on liver cells

Scienmag

Ahmed Atia and colleagues is published in Current Pharmaceutical Biotechnology, 2020 Palm oil contains abundant quantities of vitamin E compounds, which include tocopherols and tocotrienols. While tocopherol is a widely known and researched compound, […].

article thumbnail

This week in drug discovery (8-12 April) 

Drug Discovery World

The cancer research news has been coming thick and fast from the American Association of Cancer Research (AACR) Annual Meeting in San Diego this week, so our Friday round-up focuses on drug discovery in oncology. News round-up for 8-12 April by DDW Digital Content Editor Diana Spencer.

Drugs 52
article thumbnail

ESMO 2022: the evolution of TIL therapy – a highly promising approach

Pharmaceutical Technology

Successful TIL therapy depends on the infusion product containing tumour-reactive T cells that, on infusion, generate an anti-tumour immune response that causes disease regression. The use of engineered immune cytokines that selectively induce the expansion of TILs is being investigated as an alternative to IL-2 stimulation.

article thumbnail

Virios Therapeutics, Inc. Announces Research Collaboration to Explore Role of HSV-1 in Irritable Bowel Syndrome

The Pharma Data

Nasdaq: VIRI), a biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, announced today that it is entering a collaboration with Dr. Michael Camilleri of the Mayo Clinic to explore the role of antiviral therapy in managing Irritable Bowel Syndrome (IBS).